Clinic
Acadian Medical Provider
Acadian Medical Provider was paid $3.83M by Medicaid between Jan 2018 and Dec 2024, across 47 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 52% of everything it billed.
33Billing provider infoACADIAN MEDICAL PROVIDER
LINCOLN PARK, MI 48146
LINCOLN PARK, MI 48146
33aNPI1720456866assigned 09/07/2015
33bProvider typeUrgent Care Clinic/Center
28Total paid$3.83M
24GClaims102,240
24DCodes billed47
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in Michigan
Rank by total paid#18 of 239
Median peer was paid$346K
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,315 | $208K | |
| 2019 | 5,038 | $229K | |
| 2020 | 13,844 | $480K | |
| 2021 | 28,037 | $960K | |
| 2022 | 25,592 | $889K | |
| 2023 | 13,163 | $533K | |
| 2024incomplete | 12,251 | $531K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 52% | 35,184 | 30,197 | $2.01M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 15% | 8,625 | 8,579 | $575K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 11% | 13,177 | 11,531 | $431K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 8.1% | 12,420 | 10,922 | $310K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.6% | 1,994 | 1,823 | $99K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.4% | 1,325 | 1,250 | $93K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.9% | 3,501 | 3,163 | $71K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 1.0% | 708 | 708 | $39K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 411 | 410 | $38K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,477 | 3,272 | $38K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,621 | 3,170 | $29K |
| S9083 | Global fee urgent care centers | <1% | 822 | 676 | $19K |
35 more codes
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,068 | $18K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 375 | $13K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,327 | $12K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 225 | $6K |
| 87428 | <1% | 144 | $5K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 200 | $3K |
| 99195 | <1% | 59 | $3K | |
| 93923 | <1% | 37 | $3K | |
| 99201 | <1% | 78 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 936 | $3K |
| 95923 | <1% | 33 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,569 | $2K |
| 81001 | <1% | 1,147 | $1K | |
| 95921 | <1% | 29 | $1K | |
| 99072 | <1% | 3,499 | $1K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 47 | $1K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 44 | $871.50 |
| 87420 | <1% | 169 | $852.48 | |
| 99001 | <1% | 986 | $820.72 | |
| 81025 | <1% | 61 | $377.94 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 691 | $363.74 |
| 0011A | <1% | 12 | $264.95 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 184 | $253.73 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 186 | $243.66 |
| 93040 | <1% | 29 | $188.06 | |
| 99000 | <1% | 121 | $180.70 | |
| 73130 | <1% | 13 | $167.02 | |
| 81002 | <1% | 47 | $118.31 | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 2,547 | $111.25 |
| 90715 | <1% | 14 | $73.53 | |
| 81005 | <1% | 41 | $32.36 | |
| G0403 | Electrocardiogram, routine ecg with 12 leads; performed as a screening for the initial preventive physical examination with interpretation and report | <1% | 14 | $11.49 |
| 3011F | <1% | 13 | $0.04 | |
| 90658 | <1% | 16 | $0.02 | |
| 90461 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRAHDI, EQDAM (MD)